LONDON – Aviadobio Ltd. has raised $80 million in a series A round to take a precision microdosed gene therapy for treating familial frontotemporal dementia into a phase I/II clinical trial.
Tune Therapeutics Inc. launched with $40 million in initial financing and plans to pursue both rare and complex disease indications with a series of epigenetic editors that employ CRISPR-Cas9 DNA recognition to modulate gene expression in a targeted fashion, without introducing potentially problematic DNA strand breaks or changes to the genetic code.
Abogen Biosciences Co. Ltd. has raised $300 million in a series C+ round to support the development of its mRNA products, specifically to support the development of its COVID-19 mRNA vaccine and expand to the global market.
Apollo Health Ventures raised $180 million for a new venture capital fund focused on biotechnology companies developing therapies for age-related diseases. It may also invest in healthtech and digital health opportunities, but the latter constitute a minority pursuit for an investment team that is building up capabilities and expertise in disease biology.
LONDON – Quell Therapeutics Ltd. has raised $156 million in an oversubscribed series B, enabling it to start a phase I/II trial of its engineered T regulatory (Treg) cell therapy for promoting long-term immune tolerance in liver transplant patients, averting the need for chronic immunosuppression.